- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
On 6ix: 6ix.com/news/bridgebio-presents-detailed-positive-results-from-phase-3-attribute-cm-study-of
Watch BridgeBio Pharma's latest callBridgebio Pharma (NASDAQ:BBIO) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Bridgebio Pharma (NASDAQ:BBIO) Q2 2026 Earnings CallBridgeBio Pharma's next earnings callBridgebio Pharma (NASDAQ:BBIO) Q3 2026 Earnings Call · Oct 29, 2026 at 4:30 PM EDTRegister
Story so far
- BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
- BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
- BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
Earlier from BridgeBio Pharma
- BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
- BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
- BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
- BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
- BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
Later from BridgeBio Pharma
- BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
- BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
- BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
- BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Follow BridgeBio Pharma into a list and get an email when it puts out news.
Follow BridgeBio Pharma